The product is under Phase 2/3 clinical trials in China for the treatment of Acute Promyelocytic Leukemia (APL). OMS0728, having a specific binding affinity with retinoic receptor (RARα). China is an advanced country of APL treatment where the current marketed products, such as ATRA (ALL-trans retinoic acid) and Arsenic trioxide are used. However, opinion leaders of APL chemotherapy expect the advantageous profile of OMS0728 as an orally effective drug because of the safety issue and inconvenient of the current marketed drugs.